CytomX

Santa Barbara, United States Founded: 2008 • Age: 18 yrs Listed
Probody therapeutics are developed for cancer treatment.

About CytomX

CytomX is a publicly listed company based in Santa Barbara (United States) founded in 2008. Probody therapeutics are developed for cancer treatment. It operates on a HealthTech model. CytomX has raised $135.62 million across 9 funding rounds from investors including Fidelity Investments, HHS and Canaan. The company has 121 employees. CytomX has completed 1 acquisition, including clinomicslabs.net. Its website cytomx.com draws about 18 thousand monthly visits. CytomX offers products and services including Probody Therapeutics. Its focus areas include Biotechnology and Cancer Therapeutics. Its legal entity is CytomX Therapeutics, Inc. Its competitors include Revolution Medicines, Blueprint Medicines and Syndax; 3 of its 3 listed competitors have raised funding.

Company details

CytomX Therapeutics, Inc. is engaged in the research and development of novel cancer treatments through its proprietary Probody platform. The company operates in the biopharmaceutical sector, aiming to create therapies that target cancer more effectively while reducing toxicity. Solutions are advanced through clinical-stage programs, with a focus on transforming patient outcomes in oncology.

  • Headquarters Santa Barbara, United States
  • Employees 121
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website cytomx.com
  • Social LinkedIn X
  • Legal Name Cytomx Therapeutics, Inc.
Key Metrics
  • Annual Revenue
    $76.2 M (USD)
    -44.82
    as on Dec 31, 2025
  • Net Profit
    -$17.37 M (USD)
    -154.5
    as on Dec 31, 2025
  • EBITDA
    -$18.19 M (USD)
    -167.96
    as on Dec 31, 2025
  • Total Equity Funding
    $135.62M (USD)

    in 9 rounds

  • Latest Funding Round
    $70M (USD), Series D

    Jun 2015

  • Investors
  • Employee Count
    121
  • Investments & Acquisitions

Products & Services of CytomX

CytomX offers a comprehensive portfolio of products and services, including Probody Therapeutics.

Probody Therapeutics
Biopharmaceuticals

Innovative cancer therapies are developed using Probody technology.

Funding Insights of CytomX

CytomX has successfully raised a total of $135.62M across 9 strategic funding rounds. The most recent funding activity was a Series D round of $70 million completed in June 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $135.62M
  • Total Rounds 9
  • Last Round Series D β€” $70M
  • First Round $208,046

    (Jun 2008)

  • Investors Count 12

All 9 funding rounds of CytomX with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2015$70MSeries D–Fidelity Investments
Jan 2015$20MSeries C–Pfizer Venture Investments
Aug 2012$12.6MSeries B–Canaan
–
Nov 2010$524,994Series B––
–
Sep 2010$30MSeries B–Third Rock Ventures
Mar 2010$2.5MSeed––
–
Jun 2009$260,910Grant––
May 2009$260,910Grant––
Jun 2008$208,046Grant––
Valuation history

12 investors in total: 12 institutional.

Investors in CytomX

CytomX has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, HHS and Canaan.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Investing in Life Sciences sectors like Healthcare and Biotechnology.
casdincapital.com
Healthcare ecosystem is supported through investment and innovation by Deerfield.
deerfield.comNew York, United States
Health-tech companies are targeted for venture capital investments.
1999perceptivelife.comNew York, United States
Venture capital firm focused on tech sectors
venrock.comPalo Alto, United States
Canaan is recognized as an early-stage venture capital firm.
1987canaan.comSan Francisco, United States
Venture capital funding is provided to early-stage life science companies.
thirdrockventures.comBoston, United States
Corporate-backed venture capital firm focused on the healthcare sector
roche.com/venturefund.htm
Venture capital is focused on healthcare by Pfizer's investment arm.
pfizer.com/partnering/areas_of_interest/venture_investmentsNew York, United States
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms
1946fidelity.comBoston, United States
Investment advisory services are provided to financial clients.
1986teklacap.comBoston, United States
Premium access

Investor details for CytomX

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of CytomX

57 people are tracked at CytomX (28 in leadership, 13 in board & advisors, 16 in team); the tracked headcount is 121.

NameRoleGroup
Madan Paidhungat
Vice PresidentLeadership
Lloyd A. Rowland
SVP, General Counsel, Secretary & Chief Compliance OfficerLeadership
Michael Kavanaugh
Chief Scientific Officer & Head of Research and Non-Clinical DevelopmentLeadership
Farooq Nomani
Sr. Director, Corporate CounselLeadership
Dylan Daniel
Vice President, Oncology & Immuno-oncology Research And Translational BiologyLeadership
Irene Franklin
Senior Director, Drug Safety & Pharmacovigilance (consultant)Leadership
Rachael Lester
Chief Business OfficerLeadership
Chris Ogden
CFOLeadership
Lindsay Yamamoto
Executive Director, Human ResourcesLeadership
Wayne Chu
Senior Vice President, Chief Medical OfficerLeadership
Christine Sterling
Executive Assistant To Chief Executive OfficerLeadership
Yihsuan Shannon Tsai
Senior Director, Head Of Bioinformatics & Computational BiologyLeadership
Olga Vasiljeva
Vice President, Platform Biology, Bioanalysis And Clinical PharmacologyLeadership
Kakali Dhar
Director of Bioanalysis, Platform Biology and BioanalysisLeadership
Mei Wang, CPA, MBA
Director, SEC Reporting and Technical AccountingLeadership
Michael Winter
Director, Platform Biology And BioanalysisLeadership
Francesco Caiazza
Associate Director, Translational BiologyLeadership
Sharad Kukreti
Head of FP&A and ProcurementLeadership
Stephanie Robertson
Senior Vice President, Alliances & Program LeadershipLeadership
Rohit Shete, CCRA
Associate Director, Clinical OperationsLeadership

37 more people are available in the full profile.

Premium access

Complete people profiles for CytomX

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of CytomX

CytomX is a publicly listed company on the NASDAQ with ticker symbol CTMX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date08 Oct 2015
  • Listed onNASDAQ: CTMX
  • Listed entityCytomX Therapeutics, Inc.
  • Exchange sectorHealth technology
  • ISINUS23284F1057
  • Share price$2.33 (-3.93% on the day) · 2026-10-13
  • Market capitalisation$506.6M
  • Price to earnings10.3
  • EPS (diluted, trailing year)$-0.46
  • Volume (last session)5,223,013

Financials of CytomX

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025$76.2M-$17.4M-$18.2M
2024$138.1M$31.9M$26.8M
2023$101.2M-$569,000-$4.3M
2022$53.2M-$99.3M-$87.8M
2021$37.3M-$115.9M-$110.2M
Premium access

Detailed financial statements for CytomX

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Investments & Acquisitions by CytomX

CytomX has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include clinomicslabs.net.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Medical research laboratory services are provided by Clinomics Labs.
clinomicslabs.net0Jun 2004$3.98M
Premium access

Complete acquisition details for CytomX

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of CytomX

5 dated milestones of CytomX across 11 years, from founding to its latest funding, stage changes and deals.

  1. Acquisition Acquires clinomicslabs.net.
  2. Founded CytomX is founded.
  3. Funding First funding round of $208K.
  4. Funding Latest funding round, Series D, of $70.0M.
  5. IPO Lists on the stock exchange (IPO).

Competitors of CytomX

CytomX has 3 listed competitors in our database, 3 of them funded. They include Revolution Medicines, Blueprint Medicines and Syndax.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
revmed.com2014Redwood, United States$326.29M181
Cancer therapies are developed using selective pathway inhibitors.
blueprintmedicines.com2008Cambridge, United States$115M201
Selective kinase inhibitors are developed for genomically defined cancers.
syndax.com2005Waltham, United States$198.29M107
Targeted therapies for cancer treatment are developed.
Premium access

Detailed competitors of CytomX

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of CytomX

The website of CytomX (cytomx.com) receives about 17.7K visits a month and ranks #2,633,987 among all websites worldwide, #3,598 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    17.7K

    ▲ 120.6% vs previous month

  • Unique visitors
    3.6K

    per month

  • Global rank
    #2,633,987

    among all websites

  • Category rank
    #3,598

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with CytomX. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
visterrainc.com
100%
2.5K#6,988,741View details
insmed.com
100%
68.8K#433,178View details
immunocore.com
100%
11.9K#2,192,904View details
intarcia.com
99%
View details
oncobiologics.com
oncobiologics.com
98%
#5,583,393–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 6 similar websites and full traffic analytics for CytomX

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 6 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Immunology & Cancer Therapeutics

3 companies that operate in the same segment as CytomX (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Targeted and immune-oncology drugs for cancer treatment are developed.
2010Cambridge, Massachusetts, United StatesUSD 172 M
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
2013San Francisco, California, United StatesUSD 214.78 MUSD 21.05 M211
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Cytomx

Premium access

Complete news archive for CytomX

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about CytomX

CytomX was founded in 2008.

CytomX is headquartered in Santa Barbara, United States. It is registered at Santa Barbara, California, United States.

CytomX is a funded company, having raised a total of $135.62M across 9 funding rounds to date. The company's 1st funding round was a Grant of $208.05K, raised on Jun 2008.

CytomX has 121 employees.

Annual revenue of CytomX is $76.2M as on Dec 31, 2025.

CytomX Therapeutics, Inc. is engaged in the research and development of novel cancer treatments through its proprietary Probody platform. The company operates in the biopharmaceutical sector, aiming to create therapies that target cancer more effectively while reducing toxicity. Solutions are advanced through clinical-stage programs, with a focus on transforming patient outcomes in oncology.

CytomX's top competitors include Syndax, Revolution Medicines and Blueprint Medicines.

CytomX offers Probody Therapeutics.

Yes, CytomX is publicly traded on NASDAQ under the ticker symbol CTMX.

CytomX has made 1 acquisition, including clinomicslabs.net.

CytomX has 12 investors. Key investors include Fidelity Investments, HHS, Canaan, Perceptive Advisors, and Tekla Capital Management.

CytomX operates through Cytomx Therapeutics, Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available